Post by marriott on Aug 19, 2022 0:02:29 GMT
some comments CEO Erck made during his opening remarks at the last conference call :
" Through our commercial readiness efforts and global label expansion to-date, we believe we are laying the foundation for a successful transition to a commercial market in 2023 and are poised to play a significant role in the future COVID-19 landscape. "
" I will say it one more time, this is a transformational year for the company, and we’re building on a great vaccine platform. "
" Once again, we have had a very significant quarter of achievements. We continue to take – make the transition into a commercial company, and we continue to see more and more evidence that our vaccine platform is second to none . "
________________________________________________________________________________________________________________________
I would advise Mr Erck to also communicate that Novavax executive LEADERSHIP is also in transition . Further as a shareholder , I want Mr Erck to detail the proactive steps the Management team is taking to overcome the barriers associated with reaching a commercial status MINDSET .
Mr Erck also stated " But as I’ve already said, we also have a number of uncertainties that we are constantly managing. " .......Well , businesses are faced with challenges every day . As an investor in Novavax, I am more uncertain of the company's Executive management's evolving skillsets than future market and business conditions .
As I have stated many times in the past , I would strongly urge the Executive team to buy Novavax shares in the open market . THEN PUT THESE SHARES WHERE YOUR ACTIONS ARE !
No disrespect is intended !
" Through our commercial readiness efforts and global label expansion to-date, we believe we are laying the foundation for a successful transition to a commercial market in 2023 and are poised to play a significant role in the future COVID-19 landscape. "
" I will say it one more time, this is a transformational year for the company, and we’re building on a great vaccine platform. "
" Once again, we have had a very significant quarter of achievements. We continue to take – make the transition into a commercial company, and we continue to see more and more evidence that our vaccine platform is second to none . "
________________________________________________________________________________________________________________________
I would advise Mr Erck to also communicate that Novavax executive LEADERSHIP is also in transition . Further as a shareholder , I want Mr Erck to detail the proactive steps the Management team is taking to overcome the barriers associated with reaching a commercial status MINDSET .
Mr Erck also stated " But as I’ve already said, we also have a number of uncertainties that we are constantly managing. " .......Well , businesses are faced with challenges every day . As an investor in Novavax, I am more uncertain of the company's Executive management's evolving skillsets than future market and business conditions .
As I have stated many times in the past , I would strongly urge the Executive team to buy Novavax shares in the open market . THEN PUT THESE SHARES WHERE YOUR ACTIONS ARE !
No disrespect is intended !